Due to its hypoergia in the lymphocytic infiltrate, cancer mutational load, and responsiveness to anti-programmed death-1/programmed death ligand-1 (PD-1/PD-L1) treatment, breast cancer was historically thought to be immunologically “cool” and “quiet”. This evidence concerns the gene CD274 and breast cancer.